BGPT: Paper Review: Drug repurposing: progress, challenges and recommendations

Explore by Goal

Quick Explanation Copied

Paper review (skeptical, evidence-focused)

This Nature Reviews Drug Discovery review argues that drug repurposing can be faster/lower-risk than de novo development because safety and early-stage work may already exist, but it is constrained by technical, mechanistic, regulatory, and IP barriers—and it recommends actions focused on data integration, compound access, clinical-trial data access, renewed safety evaluation, funding, and incentives for repurposing.

Long Explanation

Drug repurposing: progress, challenges and recommendations

Nature Reviews Drug Discovery (2018-10-12). DOI: 10.1038/nrd.2018.168

Source: review article (not a primary study).

1) Visual map of the review’s logic (what they claim → why → where it breaks)

Evidence basis: The review explicitly structures repurposing into (1) hypothesis/indication matching, (2) mechanistic assessment in preclinical models, and (3) efficacy evaluation in Phase II trials (assuming safety data).

2) What is actually “progress” in the paper?

Progress claim A — from opportunism to systematic hypothesis generation

The review contrasts historic serendipity with newer more systematic computational and experimental approaches for finding repurposable candidates.

Progress claim B — richer data sources enable multi-pronged repurposing

They emphasize large-scale data types (e.g., transcriptomics signatures; chemical structures; adverse-event profiles; GWAS; EHRs; biobanks; paired cell-line pharmacogenomics) and note that approaches can be used synergistically.

Progress claim C — better target/mechanism interrogation tools

The review discusses mechanistic assessment approaches including docking (with limitations), GWAS-informed target discovery, and experimental target engagement/binding discovery approaches.

3) The paper’s critical bottleneck: the “pipeline gap” between hypothesis and translation

What the authors themselves acknowledge: Even with lower safety-risk assumptions and sometimes preclinical/early human data, repurposing fails in practice, with failures noted to occur “mostly at the stage of phase III trials,” and additional barriers are identified as patent/regulatory/organizational hurdles.

Skeptical critique (mechanistic, not rhetorical)

Translation isn’t guaranteed by prior safety characterization. The review’s “lower failure risk” argument is framed around safety and de-risked preclinical/human work, but it still highlights the need to study “new safety liabilities” that could arise from new disease-drug interactions, populations, or dosing schedules.
Hypothesis generation can be confounded by data heterogeneity. The review stresses “big data” bottlenecks: integration, access, and the scarcity of standardized repositories for many data types beyond transcriptomics.
Docking and other computational predictions can be limited by structural data and scoring reliability. The review explicitly notes issues: missing structures for some target classes (e.g., membrane proteins), limited curated structural target databases, and concerns about docking/scoring accuracy and differences across software packages.

4) Recommendations distilled into an auditable “requirements checklist”

#1 Integrative platforms

Recommendation for better integrative platforms to reduce manual curation and integrate omics/clinical data into user-friendly analysis outputs.

#2 Industry compound access

Recommendation for improved access to industry-generated preclinical and clinical compounds, with simplified dissemination and broader academic access.

#3 Phase II–IV trial data access

Recommendation to increase access to industry-sponsored phase II–IV trial data for external mining and follow-up repurposing leads, especially from discontinued programs.

#4 Study new safety liabilities

Recommendation to assess new safety implications due to new disease context, populations, and dosing schedule changes.

#5 Funding for repurposing (esp. rare disease)

Recommendation for more funding for repurposing initiatives and technology/compound-sharing support, including innovative mechanisms for rare diseases.

#6 Incentivize repurposing (IP/regulatory)

Recommendation to address patent and regulatory barriers with improved data exclusivity periods and other legislative/financial mechanisms.

5) Counterpoints and blind spots (what the review may not fully resolve)

Review-level evidence & heterogeneity: Because this is a narrative review, the strength of any implied “best practice” depends on the cited primary studies, and systematic coverage/quantitative meta-analysis is not provided.
Data integration bottleneck may persist: The review identifies big-data integration/access difficulties (including unstructured EHR information) as a bottleneck, but it does not fully quantify how much this limits reproducibility or prospective hit rates.
Mechanistic plausibility vs assay artifacts: The review discusses docking limitations and the need for safety re-evaluation, but it does not operationalize a universal standard for “artifact-proof” mechanistic confirmation across modalities.

6) “Audit trail” note: what would most change the review’s stance?

The review’s overall stance is that repurposing has potential but needs specific systemic fixes. The most falsifying updates would be prospective demonstrations (across multiple diseases and settings) that—after improvements in data/platform/compound access and mechanistic/safety reassessment—repurposing hit rates and translational success systematically improve relative to baseline non-repurposing discovery pipelines.

Bespoke next steps on BGPT

Author reviews (BGPT deep dives)

Feedback:

Updated: April 27, 2026